Kura Oncology reported on its Q3 2025 performance (9 months ended September 30, 2025), highlighting significant pipeline milestones against widening losses and capital deployment.
Financial Performance & Liquidity Total revenue reached \(50.1M, entirely driven by the Kyowa Kirin collaboration. However, the Net Loss widened to \)(197.7M)\( YTD (from \)(154.8M)\( in 2024), with quarterly operating expenses surging to \)100.7M against lower quarterly revenue (\(20.8M), driving the operating loss. R&D spending increased significantly to \)186.7M, largely due to ziftomenib trials. The company deployed
...